Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

被引：42

作者：

Ando, Yuwa ^{[1
]}

Kawaoka, Tomokazu ^{[1
]}

Kosaka, Masanari ^{[1
]}

Shirane, Yuki ^{[1
]}

Johira, Yusuke ^{[1
]}

Miura, Ryoichi ^{[1
]}

Murakami, Serami ^{[1
]}

Yano, Shigeki ^{[1
]}

Amioka, Kei ^{[1
]}

Naruto, Kensuke ^{[1
]}

Kosaka, Yumi ^{[1
]}

Uchikawa, Shinsuke ^{[1
]}

Kodama, Kenichiro ^{[1
]}

Fujino, Hatsue ^{[1
]}

Nakahara, Takashi ^{[1
]}

Ono, Atsushi ^{[1
]}

Murakami, Eisuke ^{[1
]}

Yamauchi, Masami ^{[1
,2
]}

Okamoto, Wataru ^{[2
]}

Takahashi, Shoichi ^{[1
]}

Imamura, Michio ^{[1
]}

Chayama, Kazuaki ^{[3
,4
,5
]}

Aikata, Hiroshi ^{[1
]}

机构：

[1] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Metab, Hiroshima 7348551, Japan

[2] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima 7348551, Japan

[3] Hiroshima Univ, Collaborat Res Lab Med Innovat, Hiroshima 7348551, Japan

[4] Hiroshima Univ, Res Ctr Hepatol & Gastroenterol, Hiroshima 7348551, Japan

[5] RIKEN Ctr Integrat Med Sci, Yokohama, Kanagawa 2300045, Japan

来源：

CANCERS | 2021年 / 13卷 / 16期

关键词：

hepatocellular carcinoma; atezolizumab; bevacizumab; immune checkpoint inhibitor; tumor marker; alpha-fetoprotein; real-world practice; molecular targeted agents; MONOCLONAL-ANTIBODY; ALPHA-FETOPROTEIN; LIVER-FUNCTION; MRECIST;

D O I：

10.3390/cancers13163958

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to investigate the early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice. Forty patients with Child-Pugh class A liver function and eastern cooperative oncology group performance status 0 or 1 were enrolled. The objective response rate (ORR) at six weeks after the start of treatment, changes in alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin, incidence of adverse events (AEs), and changes in albumin-bilirubin (ALBI) score and serum ammonia level, were evaluated. Among 40 patients, 24 had histories of prior molecular targeted agents (MTAs). The ORR was 22.5% based on mRECIST. Multivariate analysis showed that an AFP ratio <1.0 at three weeks (odds ratio 39.2, 95% confidence interval CI 2.37-649.0, p = 0.0103) was the only significant factor for predicting early response. There was no significant difference in the frequency of AEs between patients receiving first-line treatments and others. Fatigue, proteinuria, and ascites were more frequent in patients who experienced prior treatment. No decrease in ALBI score or increase in serum ammonia level was observed. Our study demonstrated that AFP may be useful in assessing early response and that this treatment is safe, including in patients with prior MTA treatments.

引用

页数：13

共 25 条

[1] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[2]

European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019

[3] Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].

Ferrara, N ;

Hillan, KJ ;

Novotny, W .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335

[4] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[5] Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model [J].

Finn, Richard S. ;

Bentley, Greg ;

Britten, Carolyn D. ;

Amado, Rafael ;

Busuttil, Ronald W. .

LIVER INTERNATIONAL, 2009, 29 (02) :284-290

[6] Hepatocellular carcinoma [J].

Forner, Alejandro ;

Reig, Maria ;

Bruix, Jordi .

LANCET, 2018, 391 (10127) :1301-1314

[7] Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J].

Herbst, Roy S. ;

Soria, Jean-Charles ;

Kowanetz, Marcin ;

Fine, Gregg D. ;

Hamid, Omid ;

Gordon, Michael S. ;

Sosman, Jeffery A. ;

McDermott, David F. ;

Powderly, John D. ;

Gettinger, Scott N. ;

Kohrt, Holbrook E. K. ;

Horn, Leora ;

Lawrence, Donald P. ;

Rost, Sandra ;

Leabman, Maya ;

Xiao, Yuanyuan ;

Mokatrin, Ahmad ;

Koeppen, Hartmut ;

Hegde, Priti S. ;

Mellman, Ira ;

Chen, Daniel S. ;

Hodi, F. Stephen .

NATURE, 2014, 515 (7528) :563-+

[8] Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience [J].

Hiraoka, Atsushi ;

Kumada, Takashi ;

Tada, Toshifumi ;

Hirooka, Masashi ;

Kariyama, Kazuya ;

Tani, Joji ;

Atsukawa, Masanori ;

Takaguchi, Koichi ;

Itobayashi, Ei ;

Fukunishi, Shinya ;

Tsuji, Kunihiko ;

Ishikawa, Toru ;

Tajiri, Kazuto ;

Ochi, Hironori ;

Yasuda, Satoshi ;

Toyoda, Hidenori ;

Ogawa, Chikara ;

Nishimura, Takashi ;

Hatanaka, Takeshi ;

Ohama, Hideko ;

Nouso, Kazuhiro ;

Morishita, Asahiro ;

Tsutsui, Akemi ;

Nagano, Takuya ;

Itokawa, Norio ;

Okubo, Tomomi ;

Arai, Taeang ;

Imai, Michitaka ;

Koizumi, Yohei ;

Nakamura, Shinichiro ;

Joko, Kouji ;

Iijima, Hiroko ;

Hiasa, Yoichi ;

Kudo, Masatoshi .

CANCER REPORTS, 2022, 5 (02)

[9] Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma [J].

Hiraoka, Atsushi ;

Kumada, Takashi ;

Atsukawa, Masanori ;

Hirooka, Masashi ;

Tsuji, Kunihiko ;

Ishikawa, Toru ;

Takaguchi, Koichi ;

Kariyama, Kazuya ;

Itobayashi, Ei ;

Tajiri, Kazuto ;

Shimada, Noritomo ;

Shibata, Hiroshi ;

Ochi, Hironori ;

Tada, Toshifumi ;

Toyoda, Hidenori ;

Nouso, Kazuhiro ;

Tsutsui, Akemi ;

Nagano, Takuya ;

Itokawa, Norio ;

Hayama, Korenobu ;

Imai, Michitaka ;

Joko, Kouji ;

Koizumi, Yohei ;

Hiasa, Yoichi ;

Michitaka, Kojiro .

ONCOLOGY, 2019, 97 (06) :334-340

[10] Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis [J].

Hiraoka, Atsushi ;

Kumada, Takashi ;

Tsuji, Kunihiko ;

Takaguchi, Koichi ;

Itobayashi, Ei ;

Kariyama, Kazuya ;

Ochi, Hironori ;

Tajiri, Kazuto ;

Hirooka, Masashi ;

Shimada, Noritomo ;

Ishikawa, Toru ;

Tachi, Yoshihiko ;

Tada, Toshifumi ;

Toyoda, Hidenori ;

Nouso, Kazuhiro ;

Joko, Kouji ;

Hiasa, Yoichi ;

Michitaka, Kojiro ;

Kudo, Masatoshi .

LIVER CANCER, 2019, 8 (02) :121-129

← 1 2 3 →